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ABSTRACT 
MENSTRUAL CYCLE AND THE VASCULAR PROPERTIES OF ISCHEMIC 
PRECONDITIONING 
SHELBY RACHEL 
2019 
 
PURPOSE: A promising therapeutic intervention to counteract endothelial 
ischemia/reperfusion (I/R) injury is ischemic preconditioning (IPC). Limited data 
from ovariectomized animal models shows that estrogen deficiency abolishes the 
cardioprotective effects of IPC, whereas estrogen replacement restores 
protection. This suggests that alterations in female sex hormones, particularly 
estrogens, that occur naturally during the menstrual cycle is likely to influence the 
vascular protective properties of IPC. The aim of the present study was to identify 
how changes in female sex hormones that occur naturally during the menstrual 
cycle interfere with IPC to provide vascular endothelial protection in women.  
METHODS: Nine healthy premenopausal eumenorrheic women (age 21±1 
yr) not taking any contraceptive medications were studied in a within-subjects 
design. Primary outcomes with respect to the assessment of vascular endothelial 
function were measured during the early follicular (after onset of menses; days 1-
6) and at mid-cycle during ovulation (days 10-14 after positive urine ovulation 
test). Endothelium-dependent vasodilation was assessed by the forearm blood 
flow (FBF) response to reactive hyperemia using strain-gauge venous occlusion 
plethysmography in the absence and presence of endothelial I/R injury (20 min 
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brachial artery ischemia followed by 15 min reperfusion) when preceded by 
remote IPC (right arm: 3×5 min cycles of ischemia).  
RESULTS: In the absence of endothelial I/R injury, peak FBF to reactive 
hyperemia was similar (P=0.19) between the early follicular (19.9±6.1 ml/100ml 
tissue/min) and ovulation phases (22.1±5.9 ml/100ml tissue/min). In contrast, 
there was a significant main effect (P=0.001) of menstrual cycle phase on the 
capacity of IPC to protect against endothelial I/R injury. For example, during the 
early follicular phase, peak FBF was significantly (P=0.02) diminished 15% with 
endothelial I/R injury (from: 19.9±6.1 to 17.1±4.1 ml/100ml tissue/min) despite 
remote IPC. As a result, total FBF during the initial 30 sec of reactive hyperemia 
(area under the curve) was decreased ~18% (P=0.027) after (41.0±11.4 
ml/100ml tissue/min) compared with before (49.6±15.1 ml/100ml tissue/min) 
endothelial I/R injury. However, during ovulation, remote IPC provided a level of 
endothelial protection from I/R injury that was not observed in the early follicular 
phase. Indeed, in the presence of endothelial I/R injury, peak FBF increased 15% 
(from: 22.1±5.9 to 25.3±6.4 ml/100ml tissue/min; P=0.012). As a result, total FBF 
was well preserved (P=0.859) after (58.2±14.6 ml/100ml tissue/min) compared 
with before (58.0±13.3 ml/100 ml tissue/min) endothelial I/R injury.  
CONCLUSIONS: These data suggest that the menstrual cycle 
differentially influences the capacity of remote IPC to protect against endothelial 
I/R injury. Greater circulating estrogens during ovulation may be an important 
mediator contributing to the protective benefits of remote IPC in women.
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INTRODUCTION 
The most recent data from the American Heart Association states that the 
prevalence of cardiovascular disease (CVD) in adult women increases with age. 
For women aged 20-39, 40-59, 60-79 and 80 plus, the prevalence is 11.5%, 
39.4%, 68.6% and 86.5% of the population, respectively [1]. In fact, each year 
nearly 7 million American women develop ischemic heart disease, and of these 
~162,000 will die, mostly from acute myocardial infarction. Data in younger 
women (<55 years of age) indicate that the annual frequency of hospitalizations 
for myocardial infarction is estimated to be more than 30,000, and this rate 
increased 2% from 1997 to 2006, mostly in women in their 40s [2]. Moreover, 
women less than 65 years die more often in the first 30 days after myocardial 
infarction compared with men, and are more likely to be readmitted for 
cardiovascular complications with the first month of hospital discharge [3]. 
Compared with men of similar age, younger women, particularly 
premenopausal women, more frequently present with plaque erosion versus 
rupture, less epicardial obstruction, and more extensive coronary microvascular 
disease [3, 4]. These differences are touted as some of the main reasons why 
women are less likely to receive timely reperfusion therapy for myocardial 
infarction and when they do, often have worse outcomes in contrast to men [5-7]. 
For example, despite successful coronary revascularization with thrombolytic 
therapy, PCI, or CABG, women develop more severe bleeding complications [8], 
increased postoperative infarction, greater rates of in-hospital mortality, and non-
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cardiac organ injury [2]. In women less than 50 years of age, it is estimated that 
the risk of death following CABG is 3 times higher than men of similar age [9].  
It is logical, therefore, to suggest that despite successful reperfusion 
therapy, the greater clinical consequences in women stem in part from more 
severe vascular endothelial ischemia/reperfusion (I/R) injury [4, 8]. In women, we 
know that I/R injury is worse during the menopause transition when the vascular 
protective effects of estrogen are lost [10]. What is not clear is how the different 
phases of the cycle in premenopausal women modulate this injury and 
interventions to prevent it. Certainly, the menstrual cycle is associated with 
changes in vascular endothelial function that may intensify injury and interfere 
with protective therapies. For example, the capacity of the endothelium to 
increase blood flow (i.e., dilation), a strong predictor of vascular health, is 
vulnerable to reperfusion damage. In the early follicular phase (when estrogen is 
lowest), dilation is impaired compared with the high estrogen late follicular phase 
[11]. Vascular function is also decreased in the early luteal phase (when 
progesterone is highest) and recovers when progesterone levels decline [12]. As 
such, the menstrual cycle provides a unique way to gain insight into how 
changes in female sex hormones impact strategies to reduce I/R injury. 
Our tissues have the natural ability to protect against I/R injury through a 
process known as remote ischemic preconditioning (IPC). Remote IPC triggers 
tissue protection by exposing an arm to small cycles of arterial occlusion. 
Mediators released from the preconditioned tissue are released into the 
circulation and culminate on the remote region exposed to I/R injury to active 
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cytoprotective signaling. Experimental studies indicate that one of the major 
players with protection afforded by IPC is estrogens. Animal studies show that 
low levels of estrogen weaken protection caused by IPC, whereas estrogen 
replacement restores it [13, 14]. No human studies have been undertaken to 
determine how phases of the menstrual cycle affect protection induced by remote 
IPC. Alterations in female sex hormones, particularly estrogens, that occur 
naturally during the menstrual cycle is likely to influence the vascular protective 
properties of IPC.  
The specific aim of this research was to determine how the early and late 
follicular phases of the menstrual cycle influences the ability of remote IPC to 
provide vascular endothelial protection against I/R injury in women. We 
hypothesize that remote IPC will not work as well in the early phase when 
estrogen is low but will recover in the late follicular phase when estrogen rises.  
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METHODS 
Subjects  
Nine sedentary, healthy, non-medicated, eumenorrheic premenopausal 
women with no history of pregnancy were studied. Women were included if they 
reported having regular menstrual cycles for the past year and not taking any 
contraceptive medications. Women were recruited from the ~6,700 women 
University students using recruitment flyers posted in the local area and sent via 
email invitation to the South Dakota State University faculty/staff and student 
body. Interested participants were e-invited to call/email the investigative team to 
discuss the nature, risks, and benefits of the project. During the initial phone 
call/email, a medical history screening form was completed to determine if 
subjects met eligibility standards. The screening form included contact 
information and general demographic information (e.g., age, sex, name, and 
racial/ethnic background) and health information (e.g., history of chronic disease, 
medication use, and exercise habits, etc.). Before participation, informed consent 
was obtained from all participants included in the study.  This study was 
submitted to and approved by the Institutional Review Board for the Protection of 
Human Subjects at South Dakota State University.  
 
Screening Procedures 
Blood Pressure measurements  
Non-dominant arm auscultatory resting systolic and diastolic blood pressure was 
measured using an appropriately sized stethoscope and sphygmomanometer 
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(Diagnostic 700 Series, American Diagnostic Corp, Hauppauge, NY) following 5 
min of seated quiet rest using standard procedures. Resting blood pressure 
measurements were performed twice and separated by 3 minutes and averaged. 
Resting heart rate was measured using a 60 second radial pulse count.  
 
Anthropometric measurements  
Standing height and body weight were measured with a digital scale (Seca 876 
digital scale, Seca Corporation, Hamburg, Germany). Abdominal waist 
circumference was assessed with a Gulick tape measured at the smallest part of 
the abdomen, above the umbilicus and below the xiphoid process to the nearest 
0.1 cm at the end of normal expiration using standard procedures. Waist 
measurements were completed twice and averaged. Percent body fat was 
estimated by air displacement plethysmography (BODPOD, COSMED USA Inc., 
Illinois). Body mass index (BMI) was calculated as weight (kg)/height (m2).  
 
Cardiorespiratory fitness  
Estimates of cardiorespiratory fitness were determined using an 8-minute brisk 
treadmill walk. This walking test is suitable for low risk, apparently healthy adults. 
The first few minutes of this test consisted of placing a heart rate monitor and 
wristwatch on the subject to measure the intensity of the walk. Subjects walked 
at a brisk self-selected walking pace that equates to 50-75% of estimated 
maximum heart rate. The first 4 minutes of the walking test were at 0% 
inclination. Thereafter, the ramp of the treadmill was increased to 4% and the 
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subject maintained the same walking speed for four more minutes. The test was 
completed in 8-9 minutes following steady-state heart rate. A 3-minute cool-down 
at a slow walking speed was then completed. 
 
Experimental Design 
Determination of menstrual phase  
Figure 1 highlights the main experimental protocol. Utilizing a within-subjects 
crossover design, primary outcomes were assessed during the early follicular 
(after onset of menses; days 1-6) and at mid-cycle during the late follicular phase 
(days 10-14; after positive ovulation test; urine ovulation prediction kits, Clearblue 
Advanced Digital Ovulation, Inverness Medical Innovations, Inc.). The Clearblue 
system is a common, accurate over-the-counter test kit that uses a urine sample 
to measure reproductive hormones in 3 minutes (similar to urine pregnancy 
tests). Current day of the cycle was recorded during the initial screening visit. 
Subjects were then scheduled for the assessment of endothelial function during 
the closest cycle phase. As a result, for the assessment of the primary outcome 
of endothelial function, 6 subjects completed the study during the early follicular 
phase first, whereas 3 subjects completed it during ovulation first.  
Figure 1. Overview of the experimental protocol 
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Endothelium-Dependent Vasodilation 
 
All procedures will take place in a temperature-controlled (22.5˚C) ~500 ft2 
vascular protection research laboratory in the Department of Health & Nutritional 
Sciences. Prior to each session, subjects reported to the research laboratory 
following an overnight fast without caffeine (~10 hours) and were instructed to 
refrain from purposeful exercise >24 hr prior to the studies. 
The capacity of the resistance arteries in the left arm to vasodilate was 
assessed by the FBF response to reactive hyperemia using strain-gauge venous 
occlusion plethysmography as previously described [15]. We have elected to use 
reactive hyperemia as our method to quantify endothelial function because it is 
most relevant to the physiological circumstances surrounding the abrupt increase 
in blood flow with I/R injury than other established methods (i.e., vasoactive drug 
infusions). With the forearm supported above the heart, a high-pressure cuff was 
inflated for 5 min to interrupt inflow of the brachial artery (DE Hokanson, Inc.). 
Cuff location and duration of ischemia were chosen to be consistent with 
established reactive hyperemia protocols by other investigators [16-18]. At 5 min 
of ischemia, the cuff was deflated. Immediately thereafter, inflation pressure of 
the same cuff was set to 50 mmHg at a 4:3 sec inflation:deflation cycle [18] to 
assess the reactive hyperemic response. At this cycle rate, we obtained one FBF 
measurement every 7 sec during the first min of hyperemia (~8 FBF recordings). 
Thereafter, a 7:7 sec inflation:deflation cycle was used for the remainder of 
hyperemia. The total duration for each assessment of endothelium-dependent 
vasodilation was 15 minutes. This procedure was completed at baseline and 
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repeated after endothelial I/R injury in the presence of remote IPC. 
 
Remote IPC and Endothelial I/R Injury 
Remote IPC was induced after the initial assessment of endothelial function 
(described above). Briefly, a high-pressure cuff was placed on the right upper 
arm and inflated to 220 mmHg (EC20 rapid cuff inflator, DE Hokanson, Inc., 
Bellevue, WA) for 5 min, followed by 5 min of deflation while the subject rested in 
a supine position. This procedure will be repeated two additional times. A 10 min 
washout was initiated following the last 5 min reperfusion phase. Immediately 
thereafter, a high-pressure cuff was inflated to 220 mmHg on the left arm for 20 
min, followed by 15 min of reperfusion to induce endothelial I/R injury. The 
protocol of prolonged brachial arterial occlusion followed by reperfusion is a well-
established method to show endothelial I/R injury in human subjects via declines 
in vascular function that can be alleviated by remote IPC (16). Endothelium-
dependent vasodilation to reactive hyperemia in the left arm was repeated 
immediately following the 15 min reperfusion phase. Heart rate and blood 
pressure were monitored at baseline, after remote IPC and endothelial I/R injury, 
and finally at the end of the procedure.  
 
Sample Size and Statistical Analysis 
Chan et al. (2001) showed in 15 healthy women, that endothelial function 
was significantly enhanced during midcycle (flow-mediated dilation of 10.9 ±1.4% 
compared with that during the early menstrual phase (8.0±1.1%). The equates to 
9 
an absolute reduction of in reactive hyperemia of ~30% in the early follicular 
phase. Prior clinical studies with remote IPC and endothelial function indicates 
that endothelial I/R-injury blunts forearm vasodilation by 20-50%. Therefore, we 
applied a 30% decrease in reactive hyperemia-induced vasodilation following 
endothelial I/R-injury in the presence of remote IPC in women during the early 
follicular phase. Using this estimate, sample sizes were calculated based on 90% 
power at an alpha level of 0.05 to detect absolute mean reductions in peak 
reactive hyperemia vasodilation of 3.3% (i.e., flow-mediated dilation of 11% 
versus 7.7% after endothelial I/R injury). Corresponding effect sizes were 1.4. 
Resulting samples size was 12 subjects. Therefore, the selection of 12 women 
achieves 90% power to detect a mean two-tailed absolute difference of 3.3% in 
reactive hyperemia with an estimated standard deviation of 1%.  
Data were checked for normality and spread and were normally 
distributed. Measures of central tendency were used to calculate subject 
characteristic data. The primary qualitative outcome was the difference in FBF 
before and after endothelial I/R injury between the early and late follicular phases 
of the menstrual cycle. Differences in peak FBF and total blood flow (area under 
the curve) responses to reactive hyperemia before and after endothelial I/R injury 
within menstrual cycle phase was determined by Paired T test. Differences in the 
capacity of remote IPC to protect against endothelial I/R injury between 
menstrual cycle phase were calculated as the percent change in peak FBF from 
baseline and analyzed by repeated measures ANOVA. Statistical significance 
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was set at P<0.05. Data represent mean±SD. Data was analyzed using IBM 
SPSS Statistics Version 25.0 (Armonk, NY: IBM Corp).
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RESULTS 
As shown in table 1, participants were normal weight based on BMI, 
normotensive, and presented with average V̇O2max values in 75-80th percentile 
for age and sex [19]. 
 
Table 1. Subject characteristics  
Variable Total Group (N=9) 
Age, year         22  1 
Body mass, kg         69.1  9.2 
BMI, kg/m
2
         21.4  1.4 
Body fat, % 26.3  6.4 
Waist circumference, cm 76.5  7.9 
V̇O2max, ml/kg/min 43.2  4.9 
Systolic BP, mmHg      119  8 
Diastolic BP, mmHg         67  4 
RHR, bpm         70  9 
Values are mean  SD. BMI: body mass index; V̇O2max: maximal oxygen 
uptake; BP: blood pressure; RHR, resting heart rate. 
 
As shown in Table 2, resting heart rate remained stable during the assessment of 
endothelial function in the early (P=0.89) and ovulation phases (P=0.78). There 
was no change in blood pressure during the early follicular (P=0.24) or ovulation 
phases (P=0.39). There were no significant heart rate (P=0.79) or blood pressure 
interactions between menstrual cycle phase (P=0.80).
12 
 
 
Table 2. Heart rate and blood pressure at baseline, with remote IPC, and 
before and after endothelial I/R injury during the assessment of endothelial 
function in the early follicular and ovulation phases.  
Heart rate, bpm  
Baseline 
Remote 
IPC 
Endothelial 
I/R injury 
Study end 
Early follicular 67±10 60±6 60±9 59±9 
Ovulation 69±11 61±8 59±8 60±8 
Systolic blood pressure, mmHg 
 Baseline 
Remote 
IPC 
Endothelial 
I/R injury 
Study end 
Early follicular 124±10 115±8 117±11 120±10 
Ovulation 121±12 115±6 110±8 122±12 
Diastolic blood pressure, mmHg 
 Baseline 
Remote 
IPC 
Endothelial 
I/R injury 
Study end 
Early follicular 67±7 65±6 62±9 68±10 
Ovulation 65±7 64±6 59±8 68±12 
IPC: ischemic preconditioning; I/R: ischemia-reperfusion. Values are 
means±SD. 
 
Menstrual Cycle and Endothelium-Dependent Vasodilation 
Baseline resting FBF were similar between the early follicular phase 
(3.31±0.98 ml/100 ml tissue/min) and ovulation (3.53± 1.01 ml/100 ml 
tissue/min). As shown in Figure 2-A below, in the absence of endothelial I/R 
injury, peak FBF to reactive hyperemia was similar (P=0.19) between the early 
follicular (19.9±6.1 ml/100ml tissue/min) and ovulation phases (22.1±5.9 
ml/100ml tissue/min).  However, during the early follicular phase, peak FBF was 
significantly (P=0.02) diminished 15% with endothelial I/R injury (from: 19.9±6.1 
to 17.1±4.1 ml/100ml tissue/min) despite remote IPC (Figure 2-A), a significant 
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difference (P=0.0001) compared with ovulation. As a result, total FBF during the 
initial 30 sec of reactive hyperemia (area under the curve) was decreased ~18% 
(P=0.027) after (41.0±11.4 ml/100ml tissue/min) compared with before 
(49.6±15.1 ml/100ml tissue/min) endothelial I/R injury (Figure 2-B). During 
ovulation, remote IPC provided a level of endothelial protection from I/R injury 
that was not observed in the early follicular phase. In the presence of endothelial 
I/R injury, peak FBF increased 15% (from: 22.1±5.9 to 25.3±6.4 ml/100ml 
tissue/min; P=0.012) (Figure 2-A). As a result, total FBF was well preserved 
(P=0.859) after (58.2±14.6 ml/100ml tissue/min) compared with before 
(58.0±13.3 ml/100 ml tissue/min) endothelial I/R injury (Figure 2-B). Total FBF 
with endothelial I/R injury was markedly higher (P=0.0001) during ovulation 
compared with the early follicular phase (Figure 2-B). There was no influence of 
menstrual cycle sequence on the FBF responses to endothelial I/R injury.  
 
Figure 2. Peak forearm blood flow response to 5 min reactive hyperemia (A) and 
total forearm blood flow (B) at baseline and in the presence of endothelial I/R 
injury with remote IPC during the early follicular (A) and ovulation phase (B). Bars 
represent means, circles represent each subject. 
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The FBF response to 5 min reactive hyperemia is shown in Figure 3. 
During the early follicular phase (Figure 3-A) FBF responses at 30-second 
intervals up to 3 mins were approximately 15-50% lower (Figure 3-A) with 
endothelial I/R injury despite attempts to induce remote IPC. The FBF responses 
during ovulation were well preserved despite endothelial I/R injury (Figure 3-B).  
Figure 3. FBF response to 5 min reactive hyperemia at baseline and in the 
presence of endothelial I/R injury with remote IPC during the early follicular (A) 
and ovulation phase (B).  
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DISCUSSION 
The main findings of the present are that the menstrual cycle differentially 
influences the capacity of remote IPC to protect against endothelial I/R injury in 
premenopausal women. The early follicular phase caused a significantly 
diminished peak FBF and total FBF when compared to the ovulation phase, 
despite IPC. This suggests that the greater circulating estrogens during ovulation 
were an important factor contributing to the protective benefits of remote IPC. 
When endothelial I/R injury was caused, the early follicular phase had decreased 
FBF during the reactive hyperemia phase suggesting that blood flow is 
diminished at that time in comparison to before endothelial I/R injury. During the 
ovulation phase, remote IPC delivered protection from I/R injury and increased 
peak FBF significantly. Baseline resting FBF were similar between the early 
follicular phase and ovulation, as well as in the absence of endothelial I/R injury 
creating an ideal situation to detect changes in FBF in the presence of 
endothelial I/R injury.  
In women, we know that I/R injury is worse during the menopause 
transition when the vascular protective effects of estrogen are lost. What is not 
clear is how the different phases of the cycle in premenopausal women modulate 
this injury and interventions to prevent it. Certainly, the menstrual cycle is 
associated with changes in arterial function that may intensify injury and interfere 
with protective therapies. For example, the capacity of the endothelium to 
increase blood flow (i.e., dilation), a strong predictor of vascular health, is 
vulnerable to reperfusion damage. In the early follicular phase (when estrogen is 
lowest), dilation is impaired compared with the high estrogen late follicular phase 
16 
[3]. Vascular function is also decreased in the early luteal phase (when 
progesterone is highest) and recovers when progesterone levels decline [4]. 
Indeed, while it is clear that estrogen exerts many vascular protective effects 
(e.g., stimulates dilation by enhancing nitric oxide production) [20], its deficiency 
contributes to alterations in cardioprotection and declines in vascular endothelial 
function across the menopause transition [21]. Limited data from animal models 
suggests that estrogen deficiency interferes with ischemic conditioning to defend 
the blood vessels from injury [5], yet these findings have not been documented in 
women.  As such, the menstrual cycle provides a unique way to isolate the 
independent effects of female sex hormones on reperfusion injury. 
Understanding how estrogen and the menstrual cycle play a role in protecting the 
endothelium can clinically impact how women are treated when presenting with 
cardiovascular implications. In the present study, we showed that protection in 
the endothelium from I/R injury was diminished in the early follicular phase. 
Ovulation on the other hand was linked with significantly better protection. 
Impaired endothelial function plays a critical role in the development of I/R injury 
and is a significant predictor of atherosclerotic events [22]. These findings are 
important because they may shed light on why, despite successful reperfusion 
therapy, younger women are at risk of greater clinical consequences associated 
with I/R injury. Many of these consequences are due to more severe injury to the 
microvasculature endothelium [4, 8]. Future research should establish guidance 
in scheduling planned medical interventions that induce I/R injury during the 
phase of the cycle with the greatest potential for cell protection. 
17 
 
Currently, most research investigating IPC is completed with healthy 
animal models that do not translate well or mimic humans in clinical settings. This 
study is novel in that it is the first human study to investigate the influence of the 
menstrual cycle on IPC-mediated protection. The findings of the study are in line 
with prior animal models. Previous data from ovariectomized animal models 
shows that estrogen deficiency abolishes the cardioprotective effects of IPC, 
whereas estrogen replacement restores protection. These models show that 
Oestrogen replacement restored the IPC effect in comparison to a placebo group 
where the cardioprotective effect of IPC was lost [13]. Using selective activation 
of protein kinase C-mediated signaling could reestablish the IPC effect without 
using Oestrogen replacement, which would facilitate the anti-inflammatory 
protection provided by the IPC in females [13]. Demerouti et al. found that IPC in 
ovariectomized rabbits resulted in weaker or lost protection and post conditioning 
significantly reduced infarct sizes [14]. 
This study has limitations. First, the sample size was small and limited to 
Caucasians. In addition, we did not determine changes in the mid-luteal phase 
when progesterone levels are high. Another limitation is that we focused 
exclusively on premenopause. Future work should investigate how 
perimenopause and postmenopause affect IPC-mediated endothelial protection. 
Lastly, it is also likely that various conceptive medications could impact IPC-
mediated protection. Future work should address this.  
In conclusion, the menstrual cycle differentially influences the capacity of 
remote IPC to protect against endothelial I/R injury. Greater circulating estrogens 
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during ovulation may be an important mediator contributing to the protective 
benefits of remote IPC in women. As emphasized in the Scientific Statement 
from the American Heart Association on Acute Myocardial Infarction, “CHD 
remains understudied, underdiagnosed, and undertreated” in American women 
[23]. Having a greater understanding of the effects of remote IPC during the early 
follicular and ovulation phases of the menstrual cycle can help lead further 
research to reduce the mortality rates for CVD in premenopausal women.
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